Get it on Google Play

FDA accepts uniQure's Huntington's disease gene therapy application

November 2, 2026 7:05 AM EST Send to a Friend
uniQure N.V. (NASDAQ: QURE) announced that the U.S. Food and Drug Administration has accepted for review a Biologics License Application ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login